SKRR Exploration Inc. V.SKRR

Theratope news in March

[DCArnold]

9th ANNUAL INTERNATIONAL SYMPOSIUM ON RECENT ADVANCES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Catamaran Resort Hotel 3999 Mission Blvd. San Diego, CA 92109 [phone] March 29-31, 2001 PROGRAM Thursday, March 29, 2001 7:00 AM Registration/Continental Breakfast STEM CELL BIOLOGY I Chairperson: Edward D. Ball, M.D. 8:00 AM Biology and Transplantation of Stem and Progenitor Cells Irving L. Weissman, M.D. 8:30 Assessing the In Vivo Potential(s) of Human Stem Cells Esmail D. Zanjani, Ph.D. 9:00 Multipotent Stem Cells in Post-Natal Bone Marrow Catherine M. Verfaillie, M.D. 9:30 Mesenchymal Stem Cells: Into the Clinic Annemarie Moseley, Ph.D., M.D. 10:00 Coffee Break CELLULAR & VACCINE THERAPY I Chairperson: Daniel Gold, Ph.D. 10:30 Effects of FLT-3 Ligand Administration on Human Peripheral Blood Dendritic Cells David N. Liebowitz, M.D., Ph.D. 11:00 Results of Breast and Ovarian Cancer Patients Treated With High Dose Chemotherapy, Autologous Transplant and Theratope Vaccine Brenda M. Sandmaier, M.D. Here is the address: https://209.75.36.91/brochures_hema_pro.html DC Arnold PS the new Theratope newsletter has been posted on Biomira's website and the NBCC's website https://www.biomira.com/tnews01q1.html https://www.natlbcc.org/pdf/theratopenews2.pdf Here's some of the text: San Antonio Breast Cancer Conference Biomira Inc. attended the San Antonio Breast Cancer Conference in December 2000 and took the opportunity to discuss the trial with interested individuals also in attendance. In total, close to 500 investigators, nurses, advocacy groups and patients stopped by our booth and took away information packages on the Phase III trial. The vaccine was also discussed at two Advocacy Group poster sessions including the National Breast Cancer Coalition (NBCC), with which we have collaboration. The Collaboration: NBCC and Biomira Inc NBCC, through its vast network of advocate groups and individuals across the United States, has quickly spread the word about the trial through its website, mass mailings, and phone contacts. Biomira is dedicated to conducting its clinical trial with input from NBCC. The relationship is fostered by frequent contact during which both groups are able to update the other on any new developments or ideas. Both NBCC and Biomira believe in the importance of conducting well-designed clinical trials and in facilitating awareness of the THERATOPE® vaccine study as a treatment option for women with metastatic breast cancer. The ultimate goal, one shared by both groups, is that answers to research questions are found, and that these answers will lead to improved treatment options for women with breast cancer. NBCC recently commented before the Oncology Drug Advisory Committee of the Food and Drug Administration. Here they stated that "public policy should discourage access to investigational drugs outside of clinical trials. Investigational treatments made available outside of clinical trials have the potential to undermine the clinical trials system." Your fellow investor, DC Arnold Thanks to lsiguy over on Yahoo for the link to the Sandmaier presentation.